Lian Brian

CEO Lian Brian sells 233,409 shares for $7.7M at blended $32.96, reducing stake 8.5% at near 52-week highs.

Lian Brian, President & CEO of Viking Therapeutics (VKTX), executed 4 separate sales totaling 233,409 shares for $7,692,120.64 on 2026-01-05, with individual transaction prices ranging from $32.29 to $35.07 and a blended average price of $32.96. This sale reduced his post-transaction holdings to 2,499,291 shares from 2,732,700 shares, representing an 8.5% reduction in his stake. The timing occurs when VKTX trades at $32.14, near its 52-week high of $42.89 (the current price is only 25.1% below the 52-week peak), and follows a 16.6% decline over the prior 30 days. His prior 4 sales at VKTX were all well-timed at the 90-day mark, with three showing declines of -22.7%, -21.5%, and -6.6%, and one showing a minor gain of +3.6%, establishing a clear pattern of sales preceding downturns. The company remains unprofitable with a net loss of $-90,787,000 for the latest quarter and zero revenue, and the CEO's sustained pattern of well-timed sells at this ticker warrants close monitoring of near-term price action.

VKTX CEO Lian Brian sold 38,989 shares at $35.01; stock now $34.93, down 55.2% from $78.03 high. All 5 prior VKTX sales were well-timed (negative 90d returns).

Lian Brian sold 38,989 shares (39.0K shares) on 2025-10-28 at $35.01, reducing holdings from 2.46M to 2.42M shares. The company is unprofitable with net income of $-90,787,000.00 and $0.00 revenue in the latest quarter. Notably, Brian's prior 5 trades at VKTX show a 100% well-timed pattern at the 90-day mark, with all sales followed by negative returns: his July 2025 sale saw 90d return of -1.6%, and his four sales in early 2025 and late 2024 were followed by 90d declines ranging from -41.7% to -47.8%. This current sale at $35.01 occurred when the stock was already down 55.2% from its 52-week high of $78.03 and up 36.6% over the prior 30 days, presenting a factual test of his historical timing pattern at this specific ticker.

VKTX CEO Brian Lian sells 26,889 shares at $27.80; prior 5 sales at ticker all well-timed with negative 90d returns.

CEO Brian Lian sold 26,889 shares at $27.80 on 2025-07-03, reducing holdings by 1.1% to 2,388,014 shares. This sale occurs as VKTX trades 63.9% below its 52-week high of $78.03 despite a recent 5.9% 30-day gain. Notably, all five of Lian's prior sales at VKTX have been well-timed, with each followed by 90-day negative returns ranging from -41.1% to -47.8%, establishing a 100% track record of selling before subsequent declines at this specific ticker. The company generated zero revenue in the latest quarter with a net loss of $-45,629,000, underscoring the stage of operations where fundamentals remain unprofitable. This pattern of consistent sell-timing at VKTX combined with the transaction during a significant drawdown from peak valuations warrants attention to whether current valuations have appropriately reflected execution risks in this clinical-stage asset.

VKTX CEO Lian Brian sells 194,490 shares for $8.3M; stock now -55.0% from 52-week high, -16.3% in 30 days

Lian Brian, President & CEO of Viking Therapeutics, executed 2 separate sales on 2025-01-06 totaling 194,490 shares for $8,313,601.16 at an average price of $42.75, reducing holdings from 2,561,060 to 2,366,570 shares. The sale occurs as VKTX trades -55.0% from its 52-week high of $94.50 and has declined -16.3% over the past 30 days and -36.2% over 90 days. Notably, the CEO's prior 5 trades at VKTX were all well-timed at the 90-day mark, with consistent negative 90-day returns ranging from -24.1% to -42.4%, suggesting a pattern of selling ahead of material declines at this specific ticker. The company remains unprofitable with net income of $-24,940,000 and zero revenue in the latest quarter, which provides fundamental context for why insider liquidation patterns may be particularly material to investors monitoring execution risk and capital allocation.

VKTX CEO Brian Lian sells 216,130 shares for $15,308,552.90 in 3 transactions at $70.43–$71.98 on 2024-09-20; holds 2,304,927 shares post-sale.

Brian Lian, President & CEO of Viking Therapeutics, executed 3 separate sales on 2024-09-20, totaling 216,130 shares for $15,308,552.90, reducing his holdings by 8.6%. The company remains unprofitable with a net income of $-22,250,000.00 and zero revenue in its latest quarter, yet maintains a $7.8B market cap. Lian's prior sales at VKTX have not been well-timed at the 90-day mark, with most recent same-ticker trades showing mixed near-term results: -1.3%, -2.9%, -4.0%, +8.4%, and +10.0% over 30 days. The stock has risen 8.8% over 30 days and 33.6% over 90 days from prior lows, currently trading at $70.47, down 25.4% from its 52-week high of $94.50. This large cash realization by the CEO occurs amid the company's unprofitability and significant recent volatility.

Lian Brian (President & CEO) sold 112,870 shares for $7,426,507.68 in 3 separate transactions at VKTX on 2024-08-19.

The CEO executed three separate sales totaling 112,870 shares (112.9K shares) for $7,426,507.68 ($7.4M) at an average price of $65.80 per share, reducing holdings by 4.6% to 2,354,927 shares (2.35M shares). The sales occurred at prices below current ($66.63) and notably -29.5% below the 52-week high of $94.50, despite a strong 30-day run of +30.9% into the transaction date. His cross-ticker track record shows 12 prior open-market sells with poor timing (90d well-timed rate 0.00%), and at VKTX specifically, his 2 prior measurable sales in February returned +140.1% and +148.4% over 30 days, indicating he sold ahead of subsequent gains rather than declines. The company is unprofitable (net income $-22.2M in the latest quarter) and operates with zero revenue, making the timing and scale of the CEO's liquidation a material data point given the risk profile and the continued elevation of the stock above pre-August levels.

CEO Lian Brian sells 115,859 shares at blended $57.58 for $6.7M amid unprofitable operations and -24.8% 90-day decline.

CEO Lian Brian executed 3 separate sales totaling 115,859 shares for $6,670,604.02 at prices ranging from $56.95 to $58.78 on 2024-07-30, reducing his holdings by 4.7% to 2,354,927 shares. The timing occurs while Viking Therapeutics remains unprofitable with net income of $-22,250,000.00 and zero revenue in the latest quarter, with market cap of $6,315,383,400.00. Over the trailing 90 days, the stock has declined 24.8% from its 52-week high of $94.50 to a current price of $57.00, placing the sale prices near the lower end of recent price action. His prior 5 sales at this ticker showed a 90-day well-timed rate of 0 of 5, meaning each prior sale was followed by subsequent gains rather than declines, suggesting a pattern of selling before upside moves rather than before downturns.